Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) Current ratio
Smith & Nephew SNATS, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 2.1×, down 0.4× from fiscal 2025 (2.6×). Over the past ten years it has ranged from 1.8× (fiscal 2023) to 2.9× (fiscal 2024); the current reading is higher than 82% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.6× | (10.92%) |
| FY2024 | 2.9× | 62.73% |
| FY2023 | 1.8× | (21.08%) |
| FY2022 | 2.2× | 8.30% |
| FY2021 | 2.1× | (24.86%) |
| FY2020 | 2.8× | 34.24% |
| FY2019 | 2.1× | (2.00%) |
| FY2018 | 2.1× | 3.51% |
| FY2017 | 2.0× | 8.15% |
| FY2016 | 1.9× | 1.88% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 2.1× | (16.85%) |
| Dec 2025 | 2.6× | (14.33%) |
| Jun 2025 | 3.0× | 3.98% |
| Dec 2024 | 2.9× | 15.11% |
| 18 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| PEN Penumbra, Inc. compare | 5.9× |
| TXG 10x Genomics compare | 5.7× |
| GKOS Glaukos Corporation compare | 4.6× |
| GMED Globus Medical, Inc. compare | 4.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.2× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.2× |
| PODD Insulet Corporation compare | 2.5× |
| SNN Smith & Nephew SNATS, Inc. | 2.1× |
| BRKR Bruker Corporation compare | 1.8× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement